Generic Crenessity Availability
Last updated on Apr 10, 2025.
Crenessity is a brand name of crinecerfont, approved by the FDA in the following formulation(s):
CRENESSITY (crinecerfont - capsule;oral)
-
Manufacturer: NEUROCRINE
Approval date: December 13, 2024
Strength(s): 25MG [RLD], 50MG [RLD], 100MG [RLD]
CRENESSITY (crinecerfont - solution;oral)
-
Manufacturer: NEUROCRINE
Approval date: December 13, 2024
Strength(s): 50MG/ML [RLD]
Is there a generic version of Crenessity available?
No. There is currently no therapeutically equivalent version of Crenessity available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Crenessity. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Treatment of congenital adrenal hyperplasia
Patent 10,905,690
Issued: February 2, 2021
Inventor(s): Grigoriadis; Dimitri E.
Assignee(s): Neurocrine Biosciences, Inc. (San Diego, CA)CRF.sub.1 receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.
Patent expiration dates:
- January 21, 2035✓
- January 21, 2035
-
Treatment of congenital adrenal hyperplasia
Patent 11,311,544
Issued: April 26, 2022
Inventor(s): Grigoriadis; Dimitri E.
Assignee(s): Neurocrine Biosciences, Inc. (San Diego, CA)CRF.sub.1 receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.
Patent expiration dates:
- January 21, 2035✓
- January 21, 2035
-
Treatment of congenital adrenal hyperplasia
Patent 11,730,739
Issued: August 22, 2023
Inventor(s): Grigoriadis; Dimitri E.
Assignee(s): Neurocrine Biosciences, Inc. (San Diego, CA)CRF.sub.1 receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.
Patent expiration dates:
- January 21, 2035✓
- January 21, 2035
-
Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine
Patent 12,128,033
Issued: October 29, 2024
Inventor(s): Becker; Andrew et al.
Assignee(s): Neurocrine Biosciences, Inc. (San Diego, CA); Sanofi (Paris, FR)The present disclosure relates to the fields of chemistry and medicine, more particularly to processes for making 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thi-azol-2-amine (Compound 1), pharmaceutically acceptable salts, and crystalline forms thereof, for the treatment of congenital adrenal hyperplasia (CAH).
Patent expiration dates:
- June 9, 2041✓✓
- June 9, 2041
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- December 13, 2029 - NEW CHEMICAL ENTITY
- December 13, 2031 - ADJUNCTIVE TREATMENT TO GLUCOCORTICOID REPLACEMENT TO CONTROL ANDROGENS IN ADULTS AND PEDIATRIC PATIENTS 4 YEARS OF AGE AND OLDER WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA (CAH)
More about Crenessity (crinecerfont)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: adrenal corticosteroid inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.